Occurrence of Mallory-Weise syndrome after chemotherapy for lung cancer has been rarely reported. [1] [2] [3] We observed a case of MalloryWeise syndrome following oral erlotinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI).
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A 68-year-old woman presented with lung adenocarcinoma. The patient had metastases to lungs, bones, and cervical lymph nodes.
Chemotherapy with cisplatin plus pemetrexed, docetaxel, and gemcitabine plus bevacizumab was done for the disease. Seventeen months later the initiation of first-line chemotherapy, a recurrence in pulmonary nodules was observed in chest CT scan. Although the patient had wild type of EGFR gene, she strongly hoped to receive EGFR-TKI therapy. Therefore, erlotinib (150 mg, once a day) was given as a fourth the Mallory-Weiss tear was self-limiting, which was confirmed by endoscopy 2 weeks later, and was managed without blood transfusions.
The most common adverse events (AEs) associated with EGFRTKIs include skin rush, diarrhea, hepatotoxicity, and pulmonary toxicity.
Among them, pulmonary toxicity is the most sensitive one, although its incidence is less than 5%. 4 The profiles are somewhat different in the three TKIs. Incidence of elevation of liver enzyme and that of diarrhea is somewhat higher than the other TKIs, respectively. In a postmarketing surveillance study of erlotinib in 10 708 Japanese patients, overall AE incidence was 81.8% (mostly grade 1/2); skin disorders (68.5%) including rash (63.0%). 4 ILD-like events were reported in 158 patients (4.5% of interim population) with a mortality rate of 1.6% (55 patients). 4 In 1977, Enock reported on a patient with a Mallory-Weiss lesion following chemotherapy with 5-fluorouracil and methyl-CCNU. cytotoxic chemotherapeutic agents. They developed Mallory-Weiss syndrome within a day after cytotoxic chemotherapy, and two of them had the syndrome soon after cisplatin-induced nausea and vomiting. 2, 3 There have been two case reports of gastrointestinal bleeding. 5, 6 Bai et al. 5 reported positive fecal test in an elderly patient treated with gefitinib and erlotinib, but bleeding site was not evaluated with endoscope. Honda et al. 6 described a patient treated with gefitinib, who developed gastroesophageal variceal hemorrhage induced by metastatic liver tumor of lung cancer. The patient had not only gefitinib but also steroid therapy. 6 To our best knowledge, however, there have been no
Mallory-Weiss syndrome following EGFR-TKI therapy. The incidence of erlotinib-induced nausea is around 10% 7, 8 , but this complication may be ignored because of lack of severity. Our patient developed MalloryWeise syndrome 1 month after the initiation of erlotinib therapy. The reason why the patient had Mallory-Weiss tear was beyond our knowledge. Persistent nausea and vomiting might have relation with the development of the syndrome. Togashi et al. 9 evaluated differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with nonsmall cell lung cancer. According to their report, more adverse events including gastrointestinal bleeding were observed in the erlotinib group and in a dose dependent manner. 9 Our experience suggested that we should alert this possible complication even in the cases treated with EGFR-TKIs.
